Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study

期刊论文
出版模式：

开放获取
发表日期：

2024年7月8日

查看全文

Yael Barer,
Olga Sánchez-Soliño,
Gabriel Chodick,
Meital Grabarnik-John,
Shiran Naftelberg Blonder,
Neta li Feurestein-Ganor,
Lars Bergmann,
Connie H. Yan,
Sivan Gazit,
David Arkadir

摘要

Introduction

Early, simple predictors for long-term survival in Parkinson’s disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment.

Methods

This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival.

Results

Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3–1.7), particularly among patients aged < 75 years (1.8; 1.4–2.4).

Conclusion

In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.